US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

48.98

-0.0100-0.02%

Post-market: 48.980.00000.00%16:10 EST

Volume:156.46K

Turnover:7.66M

Market Cap:4.23B

PE:272.05

High:49.47

Open:48.84

Low:48.50

Close:48.99

52wk High:79.17

52wk Low:44.03

Shares:86.38M

Float Shares:15.07M

Volume Ratio:0.90

T/O Rate:1.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.1800

EPS(LYR):-0.4600

ROE:5.34%

ROA:1.43%

PB:1.67

PE(LYR):-106.48

Loading ...

Overview Company News Filings

Evommune's Stock Surges On Strong Results For New Eczema Drug

Benzinga_recent_news

Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Unlocking the Potential of Multi-Indication Drugs: Can NLRP3 Give Rise to the Next Blockbuster?

Time Technoplast Unit Signs Distribution Deal with Bulgaria's Monbat AD

MT Newswires Live

T-Mobile USA schließt mehrjährigen Vertrag mit Amdocs zur Unterstützung von Kundenservice und Betrieb

Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology

Digitus Group Associate Co Signs 11.1 Mln Dinars Banking Facilities Agreement

Digitus Group Signs MoU With Schneider Electric

Nio: Multi‑Engine Growth Story With Premium Mix, AD Tech, and Global Expansion Justifying Buy Rating

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Sanofi Plans Regulatory Filings For Dupixent's Successor Despite Mixed Data From Pivotal Studies

Benzinga_recent_news

Digitus Group Signs Agreement With Stc Kuwait For Providing Off‑Grid Energy Supply Services

Acura Pharmaceuticals Relies on New AD Pharma Financing

Press Release: EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer's therapy into clinical Phase 2

A Look At Array Digital Infrastructure (AD) Valuation After US$1.018b Spectrum Sale And Special Dividend

Simply Wall St.

Array Digital rises 8.1%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":48.98,"timestamp":1770757200000,"preClose":48.99,"halted":0,"volume":156460,"hourTrading":{"tag":"盘后","latestPrice":48.98,"preClose":48.98,"latestTime":"16:10 EST","volume":1003,"amount":49126.94,"timestamp":1770757805078,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00020412329046754675,"floatShares":15067629,"shares":86379877,"eps":0.180043,"marketStatus":"Closed","change":-0.01,"latestTime":"02-10 16:00:00 EST","open":48.84,"high":49.47,"low":48.5,"amount":7659650.957024,"amplitude":0.0198,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.180043,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":5,"adr":0,"exchange":"NYSE","adjPreClose":48.99,"preHourTrading":{"tag":"盘前","latestPrice":48.59,"preClose":48.99,"latestTime":"09:29 EST","volume":156,"amount":7571.53956,"timestamp":1770733772081,"change":-0.4,"changeRate":-0.008165,"amplitude":0.005103},"postHourTrading":{"tag":"盘后","latestPrice":48.98,"preClose":48.98,"latestTime":"16:10 EST","volume":1003,"amount":49126.94,"timestamp":1770757805078,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.899324,"impliedVol":0.3283,"impliedVolPercentile":0.6667},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15067629,"roa":"1.43%","roe":"5.34%","lyrEps":-0.46,"volumeRatio":0.899324,"shares":86379877,"dividePrice":0,"high":49.47,"amplitude":0.0198,"preClose":48.99,"low":48.5,"week52Low":44.03,"pbRate":"1.67","psRate":"1.11","week52High":79.165,"institutionHeld":0.3199,"latestPrice":48.98,"eps":0.180043,"divideRate":0,"volume":156460,"delay":0,"ttmEps":0.180043,"open":48.84,"prevYearClose":53.62,"prevWeekClose":48.75,"prevMonthClose":48.19,"prevQuarterClose":53.62,"fiveDayClose":48.92,"twentyDayClose":52.76,"sixtyDayClose":47.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"},{"market":"US","date":"2025-11-07","symbol":"AD","fiscalQuarterEnding":"2025/09","expectedEps":0.25,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.97},{"date":"2025-08-20","symbol":"AD","amount":23,"announcedDate":"2025-08-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-11","defaultRemindTime":1755696600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-19","payableDate":"2025-08-11","currency":"USD","dateTimestamp":1755662400000,"payDate":"2025-08-19"},{"market":"US","date":"2025-08-11","symbol":"AD","fiscalQuarterEnding":"2025/06","expectedEps":0.33,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":0.36},{"market":"US","date":"2025-05-02","symbol":"AD","fiscalQuarterEnding":"2025/03","expectedEps":0.37,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746158400000,"reportTimeType":"pre","actualEps":0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1764133200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-02-09","current":272.046122,"percent":0.674797,"low":-273.92211,"twenty":-182.591002,"median":33.318703,"eighty":267.107888,"high":320.844562,"avg":38.820691,"sd":230.541324,"marketCap":4211025000},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-09","current":259.475322,"twenty":-182.591002,"median":33.318703,"eighty":267.107888,"marketCap":4211025000}],"updateTime":1770776651182},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610620336","title":"Evommune's Stock Surges On Strong Results For New Eczema Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2610620336","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610620336?lang=en_us&edition=fundamental","pubTime":"2026-02-11 01:29","pubTimestamp":1770744540,"startTime":"0","endTime":"0","summary":"Evommune shares jumped after its mid-stage trial showed strong skin improvement and good safety for EVO301 in patients with moderate to severe eczema.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/10/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/10/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/02/50518722/evommunes-stock-surges-on-strong-results-for-new-eczema-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/02/50518722/evommunes-stock-surges-on-strong-results-for-new-eczema-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["AD","BK4132","EVMN","BK4217","BK4139","SMA","EASI"],"gpt_icon":0},{"id":"2610642341","title":"Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610642341","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610642341?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:00","pubTimestamp":1770724800,"startTime":"0","endTime":"0","summary":"Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership. Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis. Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe. \"Welcoming Ben to the Imagene team is the next step in executing our plans to create a focused, clinically excellent company. Ben's expertise in autoimmune and inflammatory diseases within and beyond medical dermatology, including his previous work on OX40 signaling inhibitors, is an incredible asset for our program. A recognized people leader, Ben will build and lead our clinical team, which will be essential as we focus on the execution of our Phase 2b ADAPTIVE trial in AD.\" commented Kristin Yarema, PhD, Chief Executive Officer of Imagene.\"Imagene has a compelling opportunity to make meaningful advances for pa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4007","BK4139","IMA","PBIB","BK4132","AD"],"gpt_icon":0},{"id":"2610769623","title":"MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2610769623","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610769623?lang=en_us&edition=fundamental","pubTime":"2026-02-10 10:00","pubTimestamp":1770688800,"startTime":"0","endTime":"0","summary":"TAINAN, Feb. 10, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6, its investigational oral therapy for Alzheimer's disease . The study demonstrated that TML-6 was generally well tolerated with a favorable safety profile, supporting its continued clinical development.TML-6 is designed to modulate the autolysosomal system and interconnected cellular pathways involved in protein clearance, neuroinflammation, oxidative stress, and aging-related neuronal dysfunction—key biological processes underlying the progression of Alzheimer's and Parkinson's diseases . Disruption of these pathways is increasingly recognized as central to neurodegeneration.Based on these results, MerryLife is preparing to initiate a global Phase 2 program in early Alzheimer's disease, enrolling individuals with mild cognitive impairment and mild dementia. The study is planned to include appro","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2860113/Merry_Life_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2860113/Merry_Life_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/merrylife-biomedical-reports-positive-phase-1-results-and-plans-for-global-phase-2-trial-for-tml-6-an-oral-multi-targeted-investigational-therapy-for-alzheimers-disease-302659106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","LU1169589451.USD","PD","LU1169590202.USD","BK4023"],"gpt_icon":0},{"id":"2609060713","title":"Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2609060713","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609060713?lang=en_us&edition=fundamental","pubTime":"2026-02-05 22:15","pubTimestamp":1770300900,"startTime":"0","endTime":"0","summary":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233093/0/en/Longeveron-Applauds-Passage-of-the-Mikaela-Naylon-Give-Kids-a-Chance-Act-and-Reauthorization-of-Rare-Pediatric-Disease-Priority-Review-Voucher-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4132","LGVN","BK4150","MSC","BK4575","AD"],"gpt_icon":0},{"id":"1153894846","title":"Unlocking the Potential of Multi-Indication Drugs: Can NLRP3 Give Rise to the Next Blockbuster?","url":"https://stock-news.laohu8.com/highlight/detail?id=1153894846","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153894846?lang=en_us&edition=fundamental","pubTime":"2026-02-05 16:42","pubTimestamp":1770280959,"startTime":"0","endTime":"0","summary":"Strategic decisions in biopharmaceutical pipeline development often involve a multidimensional balance of innovation, feasibility, and return on investment. Among these, the \"pipeline in a drug\"...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","AD","LU1169589451.USD","BK4023","CNS","BK4135","BBB","BK4132","IBD","LU1169590202.USD"],"gpt_icon":0},{"id":"2608334877","title":"Time Technoplast Unit Signs Distribution Deal with Bulgaria's Monbat AD","url":"https://stock-news.laohu8.com/highlight/detail?id=2608334877","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608334877?lang=en_us&edition=fundamental","pubTime":"2026-02-04 13:32","pubTimestamp":1770183139,"startTime":"0","endTime":"0","summary":"PowerBuild Batteries, a subsidiary of Time Technoplast , has entered into a business collaboration and exclusive distribution agreement with Bulgarian-based battery manufacturer Monbat AD, according to a Wednesday filing to the Indian stock exchanges.Under the multi-year commercial collaboration, PowerBuild will exclusively distribute Monbat's maintenance-free, advanced valve-regulated lead-acid stationary and reserve power battery solutions in India.The batteries will cater to the requirements of data centers, IT infrastructure, banking, and financial services institutions, and other mission-critical industrial applications.The company's shares were up over 1% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AD","BK4132"],"gpt_icon":0},{"id":"2608147800","title":"T-Mobile USA schließt mehrjährigen Vertrag mit Amdocs zur Unterstützung von Kundenservice und Betrieb","url":"https://stock-news.laohu8.com/highlight/detail?id=2608147800","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608147800?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:06","pubTimestamp":1770152796,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amdocs Ltd. published the original content used to generate this news brief via ACCESS Newswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL2CW2K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2247934214.USD","BK4561","LU0251142724.SGD","LU1621767810.EUR","IE00BMPRXQ63.HKD","LU1064131342.USD","LU0070302665.USD","LU0320765489.SGD","DOX","IE00BMPRXR70.SGD","LU0742534661.SGD","LU0640476718.USD","LU1621767737.EUR","LU0048573561.USD","LU2210149790.SGD","IE00B3S45H60.SGD","LU2095319765.USD","IE00BFMHRM44.USD","LU0708994859.HKD","LU1280957306.USD","AD","TMUS","LU2210150020.SGD","LU0170899867.USD","LU1506573853.SGD","BK4549","TDS","LU1267930573.SGD","LU0029864427.USD","BK4132","GB00BDT5M118.USD","LU1983260115.SGD","LU0205194284.USD","LU1621768206.USD","LU1316542783.SGD","LU1066053197.SGD","LU2317271919.USD","LU0276348264.USD","LU1303367103.USD","BK4559","BK4588","LU0077335932.USD","IE00B775SV38.USD","LU0208291251.USD","LU0310800379.SGD","LU1988902786.USD","LU2361044949.HKD","LU0267386448.USD","LU0251131958.USD","LU1066051225.USD"],"gpt_icon":0},{"id":"2608861639","title":"Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608861639","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608861639?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:00","pubTimestamp":1770037200,"startTime":"0","endTime":"0","summary":"XanaMIA trial fully enrolled with final results expected in November 2026SYDNEY, Feb.  03, 2026  (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW)announces that the XanaMIA pivotal Alzheimer’s ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/02/3230220/0/en/Actinogen-receives-positive-Interim-Analysis-recommendation-from-its-independent-Data-Monitoring-Committee-to-continue-the-XanaMIA-pivotal-Alzheimer-s-disease-trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD"],"gpt_icon":0},{"id":"2607045311","title":"CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2607045311","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607045311?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:14","pubTimestamp":1769778840,"startTime":"0","endTime":"0","summary":"SHENZHEN, CHINA, Jan.  30, 2026  (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/30/3229502/0/en/CMS-867-HK-8A8-SG-Ruxolitinib-Phosphate-Cream-Obtained-China-NDA-Approval-Becoming-The-First-and-Only-Targeted-Drug-for-Vitiligo-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1894683348.USD","LU0553294199.USD","BK4200","BK4081","LU2637428348.USD","EMA","CMS","LU1894683264.USD","LU2500361329.USD","BK4132","TCS","LU2346227817.USD","LU0949170772.SGD","AD","BK4588","LU0545039389.USD","LU0738911758.USD","LU1003077747.HKD","LU0661504455.SGD","BK4208"],"gpt_icon":0},{"id":"2607018517","title":"Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2607018517","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607018517?lang=en_us&edition=fundamental","pubTime":"2026-01-29 16:17","pubTimestamp":1769674620,"startTime":"0","endTime":"0","summary":"BEIJING, Jan.  29, 2026  (GLOBE NEWSWIRE) -- JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/29/3228229/0/en/Study-Results-of-Novel-TYK2-Inhibitor-Soficitinib-in-Patients-with-AD-Published-by-JAMA-Dermatology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EASI","BK4132","AMA","AD"],"gpt_icon":0},{"id":"2607709480","title":"Digitus Group Associate Co Signs 11.1 Mln Dinars Banking Facilities Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2607709480","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607709480?lang=en_us&edition=fundamental","pubTime":"2026-01-29 16:07","pubTimestamp":1769674053,"startTime":"0","endTime":"0","summary":"Jan 29 (Reuters) - DIGITUS GROUP FOR DIGITAL INFRASTRUCTURE, DATA CENTERS & COMMUNICATIONS ::*ASSOCIATE CO SIGNS 11.1 MILLION DINARS BANKING FACILITIES AGREEMENT*BANKING FACILITIES TO FINANCE CONSTRUC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nRSD4YNPgv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","TDS","AD"],"gpt_icon":0},{"id":"2606622797","title":"Digitus Group Signs MoU With Schneider Electric","url":"https://stock-news.laohu8.com/highlight/detail?id=2606622797","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606622797?lang=en_us&edition=fundamental","pubTime":"2026-01-28 18:37","pubTimestamp":1769596648,"startTime":"0","endTime":"0","summary":"Jan 28 (Reuters) - DIGITUS GROUP FOR DIGITAL INFRASTRUCTURE, DATA CENTERS & COMMUNICATIONS ::*SIGNS MOU WITH SCHNEIDER ELECTRIC FZE*MOU TO EXPLORE STRATEGIC COOPERATION ON DIGITAL INFRA, DATA CENTERS*","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nRSD7KzY3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","BK4132","AD"],"gpt_icon":0},{"id":"2606828789","title":"Nio: Multi‑Engine Growth Story With Premium Mix, AD Tech, and Global Expansion Justifying Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2606828789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606828789?lang=en_us&edition=fundamental","pubTime":"2026-01-27 19:55","pubTimestamp":1769514953,"startTime":"0","endTime":"0","summary":"Nio, the Consumer Cyclical sector company, was revisited by a Wall Street analyst today. Analyst Tim Hsiao from Morgan Stanley maintained a Buy rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nio-multi‑engine-growth-story-with-premium-mix-ad-tech-and-global-expansion-justifying-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nio-multi‑engine-growth-story-with-premium-mix-ad-tech-and-global-expansion-justifying-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AD"],"gpt_icon":0},{"id":"2606246257","title":"Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246257","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606246257?lang=en_us&edition=fundamental","pubTime":"2026-01-26 22:15","pubTimestamp":1769436900,"startTime":"0","endTime":"0","summary":"ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/26/3225715/0/en/Longeveron-Announces-FDA-Grants-Type-C-Meeting-Ahead-of-Data-Readout-for-Pivotal-Phase-2-Clinical-Trial-ELPIS-II-Evaluating-Treatment-for-Hypoplastic-Left-Heart-Syndrome-HLHS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AD","BK4023","LGVN","MSC","SAP","BK4575","BK4585","BK4132","BK4150","BK4528","BK4613","BK4588"],"gpt_icon":0},{"id":"2605477342","title":"Sanofi Plans Regulatory Filings For Dupixent's Successor Despite Mixed Data From Pivotal Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2605477342","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605477342?lang=en_us&edition=fundamental","pubTime":"2026-01-23 20:02","pubTimestamp":1769169720,"startTime":"0","endTime":"0","summary":"Sanofi released late-stage study results for amlitelimab, a new eczema drug showing strong skin improvement and good safety, with more trial data expected in 2026.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/23/Gentilly--France--March-21--2021-Sign-An.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/23/Gentilly--France--March-21--2021-Sign-An.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/26/01/50092664/sanofi-plans-regulatory-filings-for-dupixents-successor-despite-mixed-data-from-pivotal-studies","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/26/01/50092664/sanofi-plans-regulatory-filings-for-dupixents-successor-despite-mixed-data-from-pivotal-studies","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","SNY","LU0757428866.USD","LU0128526141.USD","LU0029874061.USD","SNYNF","IE00BFXG1179.USD","BK4530","BK4121","IE00BFMHRM44.USD","BK4200","BK4585","AD","BK4132","TCS","LU0390134368.USD","BK4588","CRL","LU1815336091.USD"],"gpt_icon":0},{"id":"2605669120","title":"Digitus Group Signs Agreement With Stc Kuwait For Providing Off‑Grid Energy Supply Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2605669120","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605669120?lang=en_us&edition=fundamental","pubTime":"2026-01-21 13:19","pubTimestamp":1768972791,"startTime":"0","endTime":"0","summary":"Jan 21 (Reuters) - DIGITUS GROUP FOR DIGITAL INFRASTRUCTURE, DATA CENTERS & COMMUNICATIONS KSCP ::*DIGITUS GROUP - SIGNS AGREEMENT WITH STC KUWAIT FOR PROVIDING OFFGRID ENERGY SUPPLY SERVICES*DIGITUS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nRSDbLSg0q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD","TDS"],"gpt_icon":0},{"id":"2605975144","title":"Acura Pharmaceuticals Relies on New AD Pharma Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2605975144","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605975144?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:54","pubTimestamp":1768946078,"startTime":"0","endTime":"0","summary":"An update from Acura Pharmaceuticals ( ($ACUR) ) is now available. Between December 31, 2025 and January 16, 2026, Acura Pharmaceuticals received t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acura-pharmaceuticals-relies-on-new-ad-pharma-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acura-pharmaceuticals-relies-on-new-ad-pharma-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4132","AD"],"gpt_icon":0},{"id":"2604164919","title":"Press Release: EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer's therapy into clinical Phase 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2604164919","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604164919?lang=en_us&edition=fundamental","pubTime":"2026-01-20 14:48","pubTimestamp":1768891680,"startTime":"0","endTime":"0","summary":"-- Series B financing will support Exciva's Phase 2 clinical trial of its. lead candidate, Deraphan, for agitation associated with Alzheimer's. -- Financing was co-led by EQT Life Sciences out of its LSP Dementia Fund,together with Gimv, with participation from Fountain Healthcare Partners,neuroscience therapeutics, and will support Exciva's ambition to address. STOCKHOLM, Jan. 20, 2026 /PRNewswire/ -- EQT Life Sciences is pleased to announce that its LSP Dementia Fund has co-led a EUR 51 million Series B in Exciva , a clinical-stage biopharmaceutical company developing novel therapies for behavioral symptoms associated with AD.Philip Scheltens, MD, PhD, Partner at EQT Life Sciences, said: \"This investment illustrates the potential of Exciva to bring exciting innovation to a therapeutic area where Alzheimer's patients have limited or no treatment options. We are delighted to co-lead this financing to help to realize Exciva's potential, which stands out for both the quality of its scien","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","EQT","LU1169590202.USD","LU0006061336.USD","LU1169589451.USD","BK4132","IE0002270589.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4585","BK4588","BK4213","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2604133328","title":"A Look At Array Digital Infrastructure (AD) Valuation After US$1.018b Spectrum Sale And Special Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2604133328","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604133328?lang=en_us&edition=fundamental","pubTime":"2026-01-19 16:24","pubTimestamp":1768811070,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure (AD) is back in focus after closing a US$1.018b sale of spectrum licenses to AT&T and declaring a US$10.25 per share special cash dividend tied to that transaction.\nSee our latest analysis for Array Digital Infrastructure.\nThe AT&T spectrum deal and special dividend have arrived alongside a 17.38% 90 day share price return and a 29.40% 1 year total shareholder return, while the 3 year total shareholder return above 250% suggests recent momentum rather than fading...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9031000-choice1-main-header/1585186715767","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9031000-choice1-main-header/1585186715767"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/telecom/nyse-ad/array-digital-infrastructure/news/a-look-at-array-digital-infrastructure-ad-valuation-after-us","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/telecom/nyse-ad/array-digital-infrastructure/news/a-look-at-array-digital-infrastructure-ad-valuation-after-us","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","BK4132","SPB","AD","BK4018","DCF"],"gpt_icon":0},{"id":"2603216617","title":"Array Digital rises 8.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603216617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603216617?lang=en_us&edition=fundamental","pubTime":"2026-01-14 23:07","pubTimestamp":1768403269,"startTime":"0","endTime":"0","summary":"Array Digital (AD) is up 8.1%, or $4.37 to $58.02. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/array-digital-rises-8-1-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/array-digital-rises-8-1-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AD","BK4132"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":159,"code":"91000000","status":"200"}]}}